1
项与 CART-TM4SF1 cells(Shanghai Ultra-T Immune Therapeutics ) 相关的临床试验 / Not yet recruitingN/AIIT A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System
Transmembrane 4 L Six Family Member 1 (TM4SF1) is highly expressed in many tumors of digestive system .
The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 has been generated in our good manufacturing practices (GMP) facility and the anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies.
Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 positive tumors of digestive system. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 cells will be examined in patients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or liver cancer.
Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.
100 项与 CART-TM4SF1 cells(Shanghai Ultra-T Immune Therapeutics ) 相关的临床结果
100 项与 CART-TM4SF1 cells(Shanghai Ultra-T Immune Therapeutics ) 相关的转化医学
100 项与 CART-TM4SF1 cells(Shanghai Ultra-T Immune Therapeutics ) 相关的专利(医药)
100 项与 CART-TM4SF1 cells(Shanghai Ultra-T Immune Therapeutics ) 相关的药物交易